The following announcement was released earlier today, 12 December 2007, by ValiRx Plc.
For further information:
01865 784 982
Grant Thornton Corporate Finance
Philip Secrett/Colin Aaronson
020 7383 5100
Physiomics Collaboration Update – Cancer Cell Death Model Developed
ValiRx (AIM: VAL), the cancer therapeutics company, today announces that Phase 1 of its collaboration with Physiomics plc (“Physiomics”) (AIM: PYC), the European systems biology simulation company, has been completed.
Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the Apoptosis Model.
This model, on which ValiRx believes it should be able to secure a patent, will be used to accelerate ValiRx’s own internal development programmes and as an R&D tool to be licensed out to third parties.
Already the Apoptosis Model has helped the Company reach key decisions regarding GeneICE in relation to which new cancer cells to target. For example, it has helped support the decision to focus on specific hormone resistant cancers.
Dr Satu Vainikka, CEO of ValiRx, commented:
“Systems based biology is able not only to accelerate the R&D process but also improve diagnostic and prognostic processes. We believe our Apoptosis Model represents a significant new tool for use within the pharmaceutical industry and has already received significant industry interest.”
Dr Christophe Chassagnole, COO of Physiomics added:
“We are pleased to have successfully applied our simulation technology to accelerate the development of ValiRx’s breakthrough GeneICE compounds. The respective strengths of our technologies have synergised to produce significant gains and we look forward to continuing to work with ValiRx in the future.”